TVM Capital Healthcare, an international healthcare expansion and growth capital firm, has announced a recent equity investment in San Francisco-based Human Longevity Inc. (HLI), a global leader since 2013 in advancing precision medicine in the pursuit of healthy aging, also known as longevity medicine. The investment will support the company’s growth in the US market as well as its expansion into Saudi Arabia and Southeast Asia.
Founded by Dr. J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI builds on his vision of extending healthy life spans and democratizing genomics to revolutionize how we prevent "avoidable diseases." The company is recognized as a leader in the rapidly growing longevity medicine industry, due to its deep expertise in genomics and other precision medicine fields such as imaging, along with its unparalleled longitudinal patient dataset, built on decades of research. HLI's proprietary tools for detecting gene-disease associations, including its artificial intelligence health risk and recommendation platform, provide clients with pre-symptomatic diagnoses and personalized treatments.
This investment, provided by the Saudi Arabia-focused TVM Healthcare Afiyah Fund LP, will support HLI’s expansion, with an initial focus on the Kingdom. Saudi Arabia is highly receptive to healthcare models like HLI’s and has become increasingly active in longevity science, with several government-backed initiatives, including the Saudi Human Genome Program and the Hevolution Foundation. The latter is a Riyadh-headquartered global non-profit organization that invests in scientific projects and life science companies in the longevity field.
Dr. J. Craig Venter, Co-Founder and Chief Scientific Advisor of Human Longevity, Inc., commented: “Human Longevity, Inc. is a health firm with the goal of staying ahead of aging and illness. We believe our platform will save millions of lives and significantly reduce healthcare costs in the future. TVM Capital Healthcare’s investment enables us to strengthen our global position as the most data-backed longevity practice while establishing a foothold in markets like Saudi Arabia and Southeast Asia, which recognize the potential of our approach to preventive medicine and the profound impact it will have on reducing healthcare costs.”
Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, remarked: “Our investment in HLI contributes to the transition toward the ‘healthcare of the future,’ which focuses on precision medicine, personalized care, and disease prevention—in short, true ‘health care.’ The potential long-term impact of longevity medicine on society is immense. We are excited to be part of this journey through this new investment, which supports HLI’s growth in the US while introducing the company to the Kingdom of Saudi Arabia and Southeast Asia.”
Dr. Ghida Harfouche, Partner at TVM Capital Healthcare, added: “HLI’s cutting-edge science has enabled precision medicine for disease prevention and highly personalized interventions for their clients. We are pleased to support the company in its global growth and to work with them on the democratization of healthy longevity and preventive care.”
